PreciseDx
precisedx.ai
Revenue Cycle & Medical Billing
Cancer Care Centers
Health Care
Claim pageClaim
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$35.7M
3 rounds on record
Latest round
$3.7M
Venture round · Sep 2026 · 1 mo ago
Team
51-200
employees, estimated range
The money's age
Fresh money
1 months since the last round · not hiring
Momentum
20/100
fresh money
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 23
Raised a round Venture round $3.7M · SEC Form D
May 28, 2025
Raised a round Venture round $11.2M · SEC Form D
Feb 20, 2024
Raised a round Venture round $20.7M · SEC Form D
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Sep 2026 | $3.7M | — | SEC Form D |
| Venture round | May 2025 | $11.2M | — | SEC Form D |
| Venture round | Feb 2024 | $20.7M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | PreciseDx, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Eric ConverseExecutive Officer, DirectorSEC Form D
Edward SitarExecutive OfficerSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
OncoLens is the multidisciplinary cancer care platform for tumor boards, registry automation, AI patient identification, and oncology…
We deliver cutting edge cancer care in the home - reducing costs for patients, providers, and payers.
Carcinotech revolutionizes preclinical oncology services with 3D-bioprinted tumor models, advancing cancer research and precision medicine…
Defiant gets you answers in days, not months — with the right plan, the right doctors, and Dana-Farber behind every step. Expert cancer…
Thyme Care enhances the cancer journey with expert oncology navigation and an oncology care team, partnering to improve access, outcomes…
Flux steamlines patient care delivery, scheduling, reporting, finances, and real-time insights. The new standard for care delivery.
Overview
Current standards of care in oncology can be subjective, leading to a high percentage of tumors receiving intermediate grading. As a result, many patients are forced to anxiously await the results of gene expression testing for over a month, delaying vital decisions regarding their care plan.
People
Eric Converse
Executive Officer, Director
Edward Sitar
Executive Officer
Molly Harper
Director
Paul Roma
Director
Westley Dupray
Director
Erik Lium
Director
Michael Hennessy Jr.
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
New York
United States
HQ
OncoIntelligence TM
50-200 est. staff
810 7th Ave, Suite 515, New York NY 10019